Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on May 09, 2018, 10:13:41 am
-
The Food and Drug Administration (FDA) has approved the investigational new drug application from Cocrystal Pharma for its experimental hepatitis C virus (HCV) drug CC-31244, clearing the way for a Phase IIa trial of the medication.
CC-31244 is a broad-spectrum nonnucleoside inhibitor that in earlier trials demontrated a high barrier to resistance, meaning hep C is unlikely to develop mutations associated with resistance to the drug during treatment. The medication is also active against all six genotypes of hep C and has shown a low level of toxicity in multiple types of cells.
Read more...
https://www.hepmag.com/article/fda-oks-cocrystal-pharmas-study-2-4week-hep-c-treatment